Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
Top Cited Papers
- 30 November 2012
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 67 (5), 1025-1039
- https://doi.org/10.1016/j.jaad.2012.02.010
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupSupportive Care in Cancer, 2010
- Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancerInvestigational New Drugs, 2009
- Nail Toxicity Induced by Cancer ChemotherapyJournal of Oncology Pharmacy Practice, 2009
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinibAnnals of Oncology, 2008
- Analysis of dermatologic events in patients with cancer treated with lapatinibBreast Cancer Research and Treatment, 2008
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisThe New England Journal of Medicine, 1995